However, the expression of GPRC5D in cells within the oral cavity could result in on‐target off‐tumor toxicities, particularly in the form of taste disturbance, a side effect that is often underreported in clinical trials and inadequately managed in clinical routine [1, 4]. The gene discussed is GPRC5D; the disease is neoplasm.